SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-74508"
 

Search: onr:"swepub:oai:DiVA.org:oru-74508" > Insulin detemir low...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

Kølendorf, K. (author)
Diabetes Centre, Roskilde Amtssygehus, Køge, Denmark
Ross, G. P. (author)
The Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia
Pavlic-Renar, I. (author)
Outpatient Diabetes Department, Vuk Vrhovac Institute, Zagreb, Croatia
show more...
Perriello, G. (author)
Department of Internal Medicine, University of Perugia, Perugia, Italy
Philotheou, A. (author)
Endocrine Diabetes Unit, University of Cape Town, Cape Town, South Africa
Jendle, Johan, 1963- (author)
Department of Internal Medicine, Trelleborg Hospital, Trelleborg, Sweden
Gall, M.-A. (author)
Medical Development, NovoNordisk A/S, Bagsvaerd, Denmark
Heller, S. R. (author)
Clinical Sciences Centre, Northern General Hospital, Sheffield, UK
show less...
 (creator_code:org_t)
Wiley-Blackwell Publishing Inc. 2006
2006
English.
In: Diabetic Medicine. - : Wiley-Blackwell Publishing Inc.. - 0742-3071 .- 1464-5491. ; 23:7, s. 729-735
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • AIMS: Hypoglycaemia remains a major barrier preventing optimal glycaemic control in Type 1 diabetes due to the limitations of conventional insulin preparations. We investigated whether basal-bolus therapy with insulin detemir (detemir), a new soluble basal insulin analogue, was more effective in reducing the risk of hypoglycaemia compared with NPH insulin (NPH).METHODS: In this multinational, open-label, cross-over trial, 130 individuals with Type 1 diabetes received detemir and NPH twice daily in a randomized order in combination with premeal insulin aspart (IAsp) during two 16-week treatment periods. Risk of hypoglycaemia was based on self-measured plasma glucose (SMPG) and self-reported episodes during the last 10 weeks of each period.RESULTS: Risk of nocturnal and overall hypoglycaemia was, respectively, 50% and 18% lower with detemir than with NPH (P < 0.001). A total of 19 severe hypoglycaemic episodes occurred during treatment with detemir compared with 33 with NPH (NS). HbA(1c) decreased by 0.3% point with both treatments and was comparable at 7.6% (+/- sem 0.06%, 95% confidence interval -0.106, 0.108) after 16 weeks with similar doses of basal insulin. Within-person variation in mean plasma glucose was lower with detemir than with NPH (sd 3.00 vs. 3.33, P < 0.001), as was prebreakfast SMPG (P < 0.0001).CONCLUSIONS: Detemir was associated with a significantly lower risk of hypoglycaemia compared with NPH at similar HbA1c when used in combination with mealtime IAsp. The more consistent plasma glucose levels observed with detemir may allow people to aim for tighter glycaemic control without an increased risk of hypoglycaemia.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Keyword

hypoglycaemia
insulin aspart
insulin detemir
Type 1 diabetes
within-person variation

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view